O13-4 2-year update of KTE-X19 in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3
2023; Elsevier BV; Volume: 34; Linguagem: Inglês
10.1016/j.annonc.2023.09.137
ISSN1569-8041
AutoresBijal Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Ryan D. Cassaday, Édouard Forcade, Michael Bishop, Max S. Topp, Dimitrios Tzachanis, Kristen M. O'Dwyer, Martha Arellano, Yi Lin, Maria R. Baer, Gary J. Schiller, Lang Zhou, Petra Schuberth, Behzad Kharabi Masouleh, Roch Houot,
Tópico(s)Acute Lymphoblastic Leukemia research
ResumoBrexucabtagene autoleucel (KTE-X19) is an autologous anti-CD19 CAR T-cell therapy approved in the US for adult R/R B-ALL. The overall complete remission (CR) rate (CR + CR with incomplete hematologic recovery [CRi]) in ZUMA-3 with KTE-X19 was 71% after 16.4 mo median follow-up (N=55; Shah et al. Lancet 2021 ). We report outcomes with longer follow-up in these patients (pts) and in a pooled analysis of phase (Ph) 1 and 2 pts.
Referência(s)